A Phase 1, Randomized, Double-Blind, Multi-Site, Single Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of SAR440894 vs Placebo in Healthy Adults
Latest Information Update: 05 Feb 2024
At a glance
- Drugs EVT 894 (Primary)
- Indications Chikungunya virus infections
- Focus Adverse reactions
- 09 Nov 2023 Planned End Date changed from 1 Dec 2023 to 28 Sep 2024.
- 09 Nov 2023 Planned primary completion date changed from 1 Dec 2023 to 28 Sep 2024.
- 07 Jul 2022 Planned End Date changed from 30 Jun 2022 to 1 Dec 2023.